Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. IKERVIS (ciclosporine)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

IKERVIS (ciclosporine)

Medicine - Posted on Oct 04 2022
Active substance (DCI)
  • ciclosporine
history (4)
  • 8/31/22

    IKERVIS (ciclosporine)

    Key points Disapproval of reimbursement for the treatment of severe keratitis among adult patients presenting with dry eyes ...
    CAV :
    54321
    icône flèche
  • 11/7/18

    IKERVIS (ciclosporine), médicament ophtalmologique

    Intérêt clinique insuffisant pour justifier son remboursement dans la kératite sévère. IKERVIS a l’AMM dans le traitement de...
    CAV :
    54321
    icône flèche
  • 11/9/17

    IKERVIS (ciclosporine)

    IKERVIS (ciclosporine)
    icône flèche
  • 9/23/15

    IKERVIS (ciclosporin), ophthalmic medicinal product

    In the treatment of severe keratitis with dry eye disease, no clinical benefit demonstrated compared with eye drops that do ...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • S01XA18
Manufacturer
SANTEN SAS
Presentation

IKERVIS 1 mg/ml, collyre en émulsion (code CIS : 65881230)
30 récipient(s) unidose(s) polyéthylène basse densité (PEBD) de 0,3 ml - (Code CIP : 34009 300 106 4 8)

All our publications
    Autoimmune diseases Drug therapy Eye diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
2TLsRzUmCpH8bNw9